Strata Critical Medical vs Verra Mobility
SRTA and VRRM side by side, both in transportation services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SRTA and VRRM compare
Strata Critical Medical is the larger company, worth 1.7 times as much as Verra Mobility ($487M against $280M).
On earnings, Verra Mobility is cheaper: it trades at 7.7× trailing earnings, against 10.8× for Strata Critical Medical.
Strata Critical Medical grew revenue faster over the last twelve months (66.8% versus −14.0% for Verra Mobility).
Verra Mobility keeps more of each dollar of sales as profit, with a net margin of 33.2% compared with 15.7% at Strata Critical Medical.
Strata Critical Medical scores higher on the StockData Score (17 against 12 for Verra Mobility), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SRTA | VRRM |
|---|---|---|
| Size and price | ||
| Market cap | $487M | $280M |
| Share price | $5.51 | $1.84 |
| Change, 1 year | 8.0% | −92.0% |
| Change, 5 years | −43.0% | −88.0% |
| Beta (5Y) | 1.63 | 0.54 |
| Employees | 601 | 1,901 |
| StockData Score | ||
| Total score | 17 (better) | 12 |
| Valuation score | 4 | 6 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 10.8× | 7.7× (better) |
| P/S | 1.9× (better) | 2.5× |
| P/B | 1.7× | 1.1× (better) |
| EV/EBITDA | – | 4.9× |
| P/FCF | – | 2.0× |
| PEG | – | 0.40 |
| FCF yield | −9.9% | 49.1% (better) |
| Fair value | $8.72 | $11.19 |
| Margin of safety | 36.8% | 83.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 66.8% (better) | −14.0% |
| Revenue growth, 5Y average | 44.6% | 58.5% (better) |
| Net income growth (TTM) | – | −26.0% |
| EPS growth (TTM) | – | −27.3% |
| Profitability | ||
| Gross margin | 20.6% | – |
| Operating margin | −8.0% | 112% (better) |
| Net margin | 15.7% | 33.2% (better) |
| FCF margin | −18.9% | 120% (better) |
| Return on equity | 16.0% (better) | 11.3% |
| Return on invested capital | −8.8% | 5.3% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 3.90 (better) |
| Net debt / EBITDA | – | 3.71 |
| Interest coverage | – | 2.1× |
| Current ratio | 2.64 (better) | 2.05 |
| Altman Z-score | 5.67 (better) | 0.41 |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 66.1% |
| Shareholder yield | 0.00% | 66.1% (better) |
| Ownership | ||
| Held by institutions | 63.0% | 101% |
| Held by insiders | 21.0% | 0.99% |
| Insider net buying, 12 months | −$724K | −$25.3K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.5% | 5.0% |
Go deeper
- SRTA stock overview
- SRTA income statement
- SRTA valuation and score
- VRRM stock overview
- VRRM income statement
- VRRM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.